Keytruda fails in previously treated TNBC Monotherapy with PD-1 inhibitor Keytruda pembrolizumab from Merck & Co. Inc. (NYSE:MRK) missed the primary endpoint of improving overall survival vs. physician’s choice of single agent chemotherapy in the...

The miserable performance of large cap biotechs last quarter is likely to be a boon for small- and mid-cap players this year, in more ways than one. Buysiders spent most of 2017 focusing to a...

Ocular began a double-blind, vehicle-controlled, U.S. Phase III trial to evaluate OTX-XP placed within the canaliculus in about 550 patients. Ocular Therapeutix Inc. (NASDAQ:OCUL), Bedford, Mass. Product: Sustained-release travoprost ( OTX-TP ) Business: Ophthalmic Molecular target: NA...

Ocular Therapeutix Inc. (NASDAQ:OCUL) jumped $2.41 (39%) to $8.67 on Wednesday after it announced plans for two Phase III placebo-controlled trials of OTX-TP to treat glaucoma or ocular hypertension. The company said that based on...

Top-line data from a double-blind, U.S. Phase IIb trial in 73 patients showed that 0.36 mg OTX-TP reduced IOP from baseline to day 60 by 4.8 mmHg vs. 6.4 mmHg for twice-daily timolol eye drops....

Ocular Therapeutix began a double-blind, U.S. Phase IIb trial to compare a single dose of 0.36 mg Sustained Release Travoprost vs. twice-daily timolol eye drops in about 80 patients. Ocular Therapeutix Inc. (NASDAQ:OCUL), Bedford, Mass....

Ocular Therapeutix Inc. (Bedford, Mass.) raised $23.8 million in an extension of a series D round, bringing the total raised in the round to $37.8 million. All of the company's existing institutional investors participated, including...

Ocular Therapeutix Inc. (Bedford, Mass.) reported top-line data from a Phase II trial to treat glaucoma showing that OTX-TP2 led to a reduction in mean intraocular pressure (IOP) of 6.8 mmHg from baseline to day...